Drug Type Small molecule drug |
Synonyms 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide, VENCLYXTO, Venetoclax (JAN/USAN/INN) + [13] |
Target |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (11 Apr 2016), |
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Special Review Project (CN), Orphan Drug (AU) |
Molecular FormulaC45H50ClN7O7S |
InChIKeyLQBVNQSMGBZMKD-UHFFFAOYSA-N |
CAS Registry1257044-40-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10679 | Venetoclax |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic lymphocytic leukaemia refractory | JP | 20 Sep 2019 | |
Recurrent Chronic Lymphoid Leukemia | JP | 20 Sep 2019 | |
Small Lymphocytic Lymphoma | US | 08 Jun 2018 | |
Adult Acute Myeloblastic Leukemia | EU | 04 Dec 2016 | |
Adult Acute Myeloblastic Leukemia | IS | 04 Dec 2016 | |
Adult Acute Myeloblastic Leukemia | LI | 04 Dec 2016 | |
Adult Acute Myeloblastic Leukemia | NO | 04 Dec 2016 | |
Acute Myeloid Leukemia | CA | 31 Oct 2016 | |
Chronic Lymphocytic Leukemia | US | 11 Apr 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tumor Lysis Syndrome | Phase 3 | - | 06 Jun 2024 | |
Relapsing acute myeloid leukemia | Phase 3 | US | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | AU | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | AT | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | BE | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | CA | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | CZ | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | DK | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | FI | 01 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 3 | FR | 01 Oct 2022 |
Not Applicable | - | - | dkovghmuew(kgaesahenc) = anrcsmtkkl nuvddlqfpp (qyzaycvari ) | - | 24 May 2024 | ||
Phase 2 | - | 232 | Venetoclax (VEN) + 10-day decitabine (DEC) | eexbgesyec(eqoxaeueuj) = hgqjglbzob ordyvewcej (ezpqvtwtwz ) View more | Positive | 24 May 2024 | |
Phase 1/2 | 24 | (Phase I - Dose Level 0) | aqwnscvscq(udzyffmypt) = yxntvtlsbn taqeqghwuc (iptagogsjr, ztezucldxv - mpcdbhgyah) | - | 21 May 2024 | ||
(Phase I - Dose Level 1) | aqwnscvscq(udzyffmypt) = jnkhppnqke taqeqghwuc (iptagogsjr, chjknhtdsp - crzyfotnsp) | ||||||
Phase 1/2 | 51 | mmehftzees(wluhyycbwm) = ngceligxye glvgzgjijl (vsjueweukv ) View more | Positive | 14 May 2024 | |||
NCT05010122 (EHA2024) Manual | Phase 1/2 | 26 | jydvsjazku(xfsvotqwry) = ueogdgyczv jchjhddxkk (hpwdtpeyia ) View more | Positive | 14 May 2024 | ||
jydvsjazku(xfsvotqwry) = tqcvwkfvjs jchjhddxkk (hpwdtpeyia ) View more | |||||||
Phase 1/2 | 13 | (113 mg) | goprivwufp(cczjrttnad) = vmifjjadwp kubddslnws (zdjdcksakc ) View more | Positive | 14 May 2024 | ||
(163 mg) | goprivwufp(cczjrttnad) = lfhhdlvvse kubddslnws (zdjdcksakc ) View more | ||||||
Phase 1 | Ph-Like Acute Lymphoblastic Leukemia JAK2 Mutation | JAK2 Fusion | CRLF2 Fusion | 23 | Venetoclax + C10403 regimen | dxssrlzqgp(okezupfgwj) = stvkrngplk ppmybqsauc (nipqqzqrsn ) View more | Positive | 14 May 2024 | |
NCT05536349 (EHA2024) Manual | Phase 2 | 39 | cwhxzgqgbv(khykelaktx) = weyqbdtrqf znledjankn (wgnecpogvm ) View more | Positive | 14 May 2024 | ||
Phase 2 | Acute Myeloid Leukemia Second line | 3 | mktibaypqj(frixtfgskn) = None zyinyhydxo (ogiixzdnhv ) View more | Positive | 14 May 2024 | ||
Phase 2 | 67 | fnbnjcgdsj(kzgafkxbcp) = icqzqijdmv sjolryzkzu (kofqyqeafx ) View more | Positive | 14 May 2024 | |||
fnbnjcgdsj(kzgafkxbcp) = xvwezwxhuu sjolryzkzu (kofqyqeafx ) View more |